XTL Biopharma (XTLB) Posts Breakeven Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014
April 28, 2015 7:45 AM EDTHERZLIYA, Israel, April 28, 2015 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the full year ended December 31, 2014. Â
Josh Levine, Chief Executive Officer of XTL, commented, "With the recent closing of a $4 million registered direct offering from a US based healthcare-dedicated investor... More
